Navigation Links
Onyx Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
Date:9/2/2009

EMERYVILLE, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at two healthcare conferences in September.

Robert W. Baird & Co. 2009 Health Care Conference

Onyx will present at the Robert W. Baird & Co. 2009 Health Care Conference in New York, New York, on September 9, 2009 at 9:30 a.m. Eastern Time.

Thomas Weisel Partners Healthcare Conference

Subsequently, Onyx will present at the Thomas Weisel Partners Healthcare Conference in Boston, Massachusetts, on September 10, 2009 at 12:55 p.m. Eastern Time.

Interested parties may access a live webcast of both presentations on our website at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentations will be available one hour following the conclusion of the presentations through October 9, 2009.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar((R)), a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. For more information about Onyx, visit the company's website at www.onyxpharm.com.

Nexavar((R)) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Transcept Pharmaceuticals to Present at the BioCentury Thomson Reuters Newsmakers in the Biotech Industry Conference on September 16, 2009
2. Poniard Pharmaceuticals To Present at Three Upcoming Investor Conferences in September
3. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
4. Jiangbo Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
5. Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Healthcare Conference
6. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
7. Raptor Pharmaceuticals Schedules 2009 Annual Meeting of Stockholders
8. Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria
9. Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
10. EPIX Pharmaceuticals, Inc. Announces the PRX-00023 Therapeutics CNS Program in Phase 2b/3 Will Be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
11. Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... 2017 , ... MacArthur Sotheby’s International Realty, a luxury real ... the first Delos Wellness Signature™ residence in Hawaii is on the market for ... listing agent Kelly Allen, R(S) of Carvill Sotheby’s International Realty located on Oahu, ...
(Date:8/21/2017)... Boston, MA (PRWEB) , ... August 21, 2017 ... ... healthcare consulting firm is utilizing its extensive experience with Health Economics and Outcomes ... on Electronic Health Record data. In 2014, US healthcare spending exceeded $3.0 trillion ...
(Date:8/18/2017)... ... August 18, 2017 , ... Producers of ... Federal Hybrids, Inc. in an upcoming episode, scheduled to broadcast fourth quarter 2017. ... explore Federal Hybrids, the independent, family-owned seed company. Educating audiences about its broad ...
(Date:8/17/2017)... ... August 17, 2017 , ... Cynvenio Biosystems, ... today announced the launch of a new breast cancer monitoring study in partnership ... to evaluate the potential for early detection of recurrent breast cancer using LiquidBiopsy ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 30.37% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
Breaking Biology News(10 mins):